<DOC>
	<DOC>NCT00698646</DOC>
	<brief_summary>The purpose of the study is to evaluate the safety and efficacy of initial treatment therapy with valsartan/hydrochlorothiazide (HCTZ) versus the initial treatment therapy with monotherapies (valsartan or HCTZ) in the very elderly patients (greater than or equal to 70 years) with stage 1 or 2 hypertension</brief_summary>
	<brief_title>Efficacy and Safety of Valsartan/Hydrochlorothiazide Combination Compared to Valsartan Monotherapy or Hydrochlorothiazide Monotherapy in Elderly (&gt;70) With Mild-moderate Hypertension.</brief_title>
	<detailed_description />
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>Hydrochlorothiazide</mesh_term>
	<mesh_term>Valsartan</mesh_term>
	<criteria>Age 70 years or older. Patients with hypertension prior to being randomized into study. Patients must have an office cuff MSSBP ≥ 140 and ≤ 200 mmHg systolic. Have the ability to communicate and comply with all study requirements. Provide written informed consent to participate in the study prior to any screening or study procedures. Use of other investigational drugs within 30 days of enrollment. History of hypersensitivity to any of the study drugs or to drugs of similar chemical classes. Office blood pressure measured by office machine cuff with a mean of (3) MSDBP ≥ 120 mmHg at anytime during the screening / washout period. Patients taking 3 or more antihypertensive drugs and MSSBP ≥ 160 mmHg at the time of Visit 1. Other protocoldefined exclusion criteria may apply</criteria>
	<gender>All</gender>
	<minimum_age>70 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2011</verification_date>
	<keyword>Systolic blood pressure</keyword>
	<keyword>Diastolic blood pressure</keyword>
	<keyword>Valsartan</keyword>
	<keyword>Hydrochlorothiazide</keyword>
</DOC>